JP2008538771A - テロメラーゼのプロセッシビティーを向上させるための化合物の使用 - Google Patents
テロメラーゼのプロセッシビティーを向上させるための化合物の使用 Download PDFInfo
- Publication number
- JP2008538771A JP2008538771A JP2008508062A JP2008508062A JP2008538771A JP 2008538771 A JP2008538771 A JP 2008538771A JP 2008508062 A JP2008508062 A JP 2008508062A JP 2008508062 A JP2008508062 A JP 2008508062A JP 2008538771 A JP2008538771 A JP 2008538771A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- use according
- alkynyl
- acid
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *c1c2nc[n](*OCP(*)(*)=O)c2nc(C=C)n1 Chemical compound *c1c2nc[n](*OCP(*)(*)=O)c2nc(C=C)n1 0.000 description 2
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67446605P | 2005-04-25 | 2005-04-25 | |
US67523405P | 2005-04-27 | 2005-04-27 | |
US67523505P | 2005-04-27 | 2005-04-27 | |
PCT/CZ2006/000023 WO2006114064A2 (fr) | 2005-04-25 | 2006-04-25 | Utilisation de composes d'amelioration de la capacite de traitement d'une telomerase |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008538771A true JP2008538771A (ja) | 2008-11-06 |
JP2008538771A5 JP2008538771A5 (fr) | 2009-05-21 |
Family
ID=36778204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008508062A Pending JP2008538771A (ja) | 2005-04-25 | 2006-04-25 | テロメラーゼのプロセッシビティーを向上させるための化合物の使用 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1879657A2 (fr) |
JP (1) | JP2008538771A (fr) |
AU (1) | AU2006239677A1 (fr) |
CA (1) | CA2606399A1 (fr) |
WO (2) | WO2006114064A2 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015502979A (ja) * | 2011-12-22 | 2015-01-29 | ジェロン・コーポレーションGeron Corporation | テロメラーゼ基質およびテロメア長作用因子としてのグアニンアナログ |
JP2016515128A (ja) * | 2013-03-15 | 2016-05-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 非環式ヌクレオシドホスホン酸ジエステル |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008520744A (ja) | 2004-11-19 | 2008-06-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 抗炎症性ピラゾロピリミジン |
MX2008012929A (es) | 2006-04-04 | 2008-12-17 | Univ California | Antagonistas de cinasa. |
FR2908133B1 (fr) * | 2006-11-08 | 2012-12-14 | Centre Nat Rech Scient | Nouveaux analogues de nucleotides comme molecules precurseurs d'antiviraux |
US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
SG187425A1 (en) | 2008-01-04 | 2013-02-28 | Intellikine Llc | Certain chemical entities, compositions and methods |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
WO2009114874A2 (fr) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Inhibiteurs de kinases (benzothiazole) et procédés d’utilisation associés |
JP5547099B2 (ja) | 2008-03-14 | 2014-07-09 | インテリカイン, エルエルシー | キナーゼ阻害剤および使用方法 |
JP5788316B2 (ja) | 2008-07-08 | 2015-09-30 | インテリカイン, エルエルシー | キナーゼインヒビターおよび使用方法 |
WO2010006072A2 (fr) | 2008-07-08 | 2010-01-14 | The Regents Of The University Of California | Modulateurs de mtor et leurs utilisations |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
CA2740885C (fr) | 2008-10-16 | 2018-04-03 | The Regents Of The University Of California | Inhibiteurs d'heteroarylkinase a noyau fusionne |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
WO2010129816A2 (fr) | 2009-05-07 | 2010-11-11 | Intellikine, Inc. | Composés hétérocycliques et leurs utilisations |
WO2011047384A2 (fr) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Procédés d'inhibition de l'activité ire1 |
CA2799579A1 (fr) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Composes chimiques, compositions et procedes pour modulation de kinases |
CN103298474B (zh) | 2010-11-10 | 2016-06-29 | 无限药品股份有限公司 | 杂环化合物及其用途 |
ES2637113T3 (es) | 2011-01-10 | 2017-10-10 | Infinity Pharmaceuticals, Inc. | Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas |
JP6130305B2 (ja) | 2011-02-23 | 2017-05-17 | インテリカイン, エルエルシー | キナーゼ阻害剤の組み合わせおよびそれらの使用 |
CA2842190A1 (fr) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Composes heterocycliques et leurs utilisations |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
RU2014111823A (ru) | 2011-08-29 | 2015-10-10 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения и их применения |
JP6342805B2 (ja) | 2011-09-02 | 2018-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 置換ピラゾロ[3,4−d]ピリミジンおよびその用途 |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
CN104995192A (zh) | 2012-09-26 | 2015-10-21 | 加利福尼亚大学董事会 | Ire1的调节 |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
CA2907924C (fr) | 2013-04-08 | 2022-10-25 | The Board Of Regents Of The University Of Texas System | Composes de modification de telomere a mediation par telomerase |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MX2021012208A (es) | 2013-10-04 | 2023-01-19 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos y usos de los mismos. |
MX2016012021A (es) | 2014-03-19 | 2017-04-13 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. |
US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
CN112898345A (zh) | 2014-09-15 | 2021-06-04 | 加利福尼亚大学董事会 | 核苷酸类似物 |
WO2016054491A1 (fr) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
EP3350183A1 (fr) | 2015-09-14 | 2018-07-25 | Infinity Pharmaceuticals, Inc. | Formes solides de dérivés d'isoquinolinone, leur procédé de fabrication, compositions les comprenant et méthodes d'utilisation de celles-ci |
WO2017048956A1 (fr) | 2015-09-15 | 2017-03-23 | The Regents Of The University Of California | Analogues nucléotidiques |
WO2017161116A1 (fr) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues de composés isoquinolinone et quinazolinone et leurs utilisations comme inhibiteurs de la kinase pi3k |
WO2017214269A1 (fr) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
AU2017281797A1 (en) | 2016-06-24 | 2019-01-24 | Infinity Pharmaceuticals, Inc. | Combination therapies |
MX2019007585A (es) | 2016-12-22 | 2019-09-09 | Merck Sharp & Dohme | Profarmacos de ester alifatico antiviricos de tenofovir. |
CN108948084B (zh) * | 2017-05-19 | 2020-10-20 | 浙江司太立制药股份有限公司 | 替诺福韦双-l-氨基酸酯及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000074667A2 (fr) * | 1999-06-04 | 2000-12-14 | Au Jessie L S | Methodes et compositions destinees a la modulation de l'action de medicaments par deterioration de telomeres |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057305A (en) * | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
EP0618214A1 (fr) * | 1993-04-01 | 1994-10-05 | Merrell Dow Pharmaceuticals Inc. | Dérivés phosphonates insaturés de purines et de pyrimidines |
US6716825B2 (en) * | 1999-12-03 | 2004-04-06 | The Regents Of The University Of California | Phosphonate compounds |
WO2002069949A2 (fr) * | 2001-03-06 | 2002-09-12 | Prendergast Patrick T | Polytherapie pour la reduction de la toxicite d'agents chimiotherapeutiques |
EP1418241A1 (fr) * | 2002-11-08 | 2004-05-12 | PrimaGen Holding B.V. | Procédé de quantifier le rapport de deux séquences d'acides nucléiques |
ATE445404T1 (de) * | 2004-01-21 | 2009-10-15 | Gilead Sciences Inc | Verwendung von adefovir oder tenofovir zur hemmung von mmtv-artigen viren im zusammenhang mit brustkrebs und primärer biliärer zirrhose |
-
2006
- 2006-04-25 CA CA002606399A patent/CA2606399A1/fr not_active Abandoned
- 2006-04-25 WO PCT/CZ2006/000023 patent/WO2006114064A2/fr not_active Application Discontinuation
- 2006-04-25 JP JP2008508062A patent/JP2008538771A/ja active Pending
- 2006-04-25 AU AU2006239677A patent/AU2006239677A1/en not_active Abandoned
- 2006-04-25 EP EP06722450A patent/EP1879657A2/fr not_active Withdrawn
- 2006-04-25 WO PCT/CZ2006/000024 patent/WO2006114065A2/fr not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000074667A2 (fr) * | 1999-06-04 | 2000-12-14 | Au Jessie L S | Methodes et compositions destinees a la modulation de l'action de medicaments par deterioration de telomeres |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015502979A (ja) * | 2011-12-22 | 2015-01-29 | ジェロン・コーポレーションGeron Corporation | テロメラーゼ基質およびテロメア長作用因子としてのグアニンアナログ |
JP2016515128A (ja) * | 2013-03-15 | 2016-05-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 非環式ヌクレオシドホスホン酸ジエステル |
JP2019069984A (ja) * | 2013-03-15 | 2019-05-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 非環式ヌクレオシドホスホン酸ジエステル |
Also Published As
Publication number | Publication date |
---|---|
WO2006114065A2 (fr) | 2006-11-02 |
WO2006114064A2 (fr) | 2006-11-02 |
AU2006239677A1 (en) | 2006-11-02 |
EP1879657A2 (fr) | 2008-01-23 |
CA2606399A1 (fr) | 2006-11-02 |
WO2006114064A3 (fr) | 2007-06-28 |
WO2006114065A3 (fr) | 2007-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008538771A (ja) | テロメラーゼのプロセッシビティーを向上させるための化合物の使用 | |
EP1716162B1 (fr) | Phosphonates, monophosphonamidates, bisphosphonamidates pour traiter des maladies virales | |
US8318701B2 (en) | Phosphonate analogs of HIV inhibitor compounds | |
US8324179B2 (en) | Nucleoside analogs for antiviral treatment | |
JP5969471B2 (ja) | パラミクソウイルス科ウイルス感染症を治療するための方法及び化合物 | |
US5591851A (en) | Method for synthesis | |
PT1628685E (pt) | Análogos de fosfonatos antivirais | |
WO2017148290A1 (fr) | Composé d'adénine substituée et composition pharmaceutique correspondante | |
ES2357770T3 (es) | Análogos de fosfonatos antivirales. | |
AU2011224011A1 (en) | Phosphonate analogs of HIV inhibitor compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090406 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090406 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120220 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120717 |